Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients.

Infect Drug Resist · 2023 · PMC10361278 · PMID 37484907

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Although a decreasing trend in efavirenz C max and AUC 0-18 was observed in PK2, a 29% increase in C 18h and a 13% increase in AUC 0-18 during PK3 and a maximum concentration and maximum area measured in PK4 were sufficient to maintain effective virological suppression during combination therapy.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.